Business Description
ME Therapeutics Holding Inc
NAICS : 541714
SIC : 3741
ISIN : CA5527671054
Description
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 33.68 | |||||
Equity-to-Asset | 1 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 46.09 | |||||
9-Day RSI | 48.9 | |||||
14-Day RSI | 50.96 | |||||
6-1 Month Momentum % | 383 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History |
---|
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -989.01 | |||||
ROA % | -880.3 | |||||
ROIC % | -3804.08 | |||||
ROC (Joel Greenblatt) % | -51318.52 | |||||
ROCE % | -988.66 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 69.48 | |||||
Price-to-Tangible-Book | 63 | |||||
EV-to-EBIT | -14.54 | |||||
EV-to-EBITDA | -14.54 | |||||
EV-to-FCF | -165.31 | |||||
Earnings Yield (Greenblatt) % | -6.88 | |||||
FCF Yield % | -0.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ME Therapeutics Holding Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.202 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 50.96 | ||
14-Day ATR (€) | 0.095478 | ||
20-Day SMA (€) | 2.526 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 0.5042 - 3.12 | ||
Shares Outstanding (Mil) | 25.19 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ME Therapeutics Holding Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ME Therapeutics Holding Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
ME Therapeutics Holding Inc Frequently Asked Questions
What is ME Therapeutics Holding Inc(FRA:Q9T)'s stock price today?
The current price of FRA:Q9T is €2.52. The 52 week high of FRA:Q9T is €3.12 and 52 week low is €0.50.
When is next earnings date of ME Therapeutics Holding Inc(FRA:Q9T)?
The next earnings date of ME Therapeutics Holding Inc(FRA:Q9T) is .
Does ME Therapeutics Holding Inc(FRA:Q9T) pay dividends? If so, how much?
ME Therapeutics Holding Inc(FRA:Q9T) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |